Alicia Martin is an Australian community pharmacist and the creator of an ingenious mobile app, TaperMate, which aims to help people with hyperbolic drug tapering and prescribed drug withdrawal.

Dory Previn was an American lyricist, singer-songwriter, and poet whose deeply personal work explored her struggles with mental health, including experiences of psychosis. In October 1974, she met with neuroscientist Peter Sterling for a candid conversation about her psychiatric treatment.

Psychologist Gail Hornstein discusses her search for the meanings of madness, from asylum artifacts and memoirs to the contemporary peer-support groups reshaping how people understand voices and visions.

Science is supposed to be self-correcting. But what happens when the journals entrusted to uphold this principle become its gatekeepers?

Pilling explains how Mad Studies moves from first-person knowledge to questions of sanism, psychiatric authority, mutual aid, and collective resistance.

In this wide-ranging conversation on public mental health, psychiatrization, and community care, Dinesh Bhugra explains why meaningful lives, not symptom reduction alone, should guide mental healthcare today.

I had been the one whose fear was called dangerous, distorted into a label. Now I was on the other side, being asked to do it to someone else.

Marianne Apostolides discusses how Go/No-Go grew from her search for new eating-disorder treatments into a critique of the metaphors, experiments, and technologies shaping contemporary neuroscience and psychiatry. She argues that efforts to reduce distress to circuits, algorithms, and biomarkers often overlook subjectivity, agency, and the human relationships that meaningful care requires.

The number of people referred to state hospitals as ‘Incompetent to stand trial’ (IST) has surged over the last decade. In response, states are refurbishing or rebuilding their state hospitals— even as their own experts say this will only make the crisis worse. Why?

Former FDA officials write that claims that the black warning led to an increase in youth are "factually inaccurate in ways that are directly verifiable."

The Expression of Concern published by JHP serves to inform the public that retraction of the article is now under consideration.

Dr. Howard Schubiner joins us on the MIA podcast to discuss his work and the power of neuroplasticity to address psychological or physiological pain.

Many brands promising to help women actually make their suffering worse by reinforcing the belief that menopause is a time of deterioration.

Rejected by the FDA four times; an advisory committee vote against approval. Yet in 2023, gepirone (Exxua) was approved for depression.

Physician-anthropologist Khameer Kidia examines how violence and inequality shape mental distress, arguing for patient autonomy, community care, and structural change beyond diagnosis, medication, and individualized psychiatric treatment.

Mental health professionals are trained to be technicians rather than provided with the opportunity to discover the craft of healing.

Chelsea McVeigh joins us to discuss her journey through antidepressant withdrawal. At 31, during a new pregnancy, she suffered a severe adverse reaction that turned her world upside down.

Reckoning with my own story became the vehicle for reckoning with my profession—and with what psychiatric care does to the people we care for.

Carla Delgado joins us to discuss her experience of antidepressant withdrawal and the hurdles created by dealing with a system that is largely ignorant of withdrawal and tapering.

Neither the FDA nor Neurovalens have provided the results from the clinical trial showing how well the device works or its risks.